- TheStreet.com•5 days ago
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
- Motley Fool•6 days ago
Once biotech M&A heats up again, Acadia, Bluebird, and Jazz could be the first targets on the list, according to our Motley Fool contributors.
bluebird bio, Inc.NasdaqGS
After hours: 49.310.00 (0.00%) as of 5:01 PM EDT
|Bid||48.10 x 100|
|Ask||52.00 x 100|
|52wk Range||35.37 - 169.16|
|Day's Range||47.82 - 49.64|
|Avg Vol (3m)||895,107|
As of 4:00 PM EDT. Market closed.